Form 4: Pfizer Director James Quincey Reports Acquisition of Phantom Stock Units

Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.

Summary

• On June 28, 2024, James Quincey, a director of Pfizer Inc., acquired 1,384.918 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price of the underlying common stock was $27.98.
• Following the transaction, Quincey directly owns 50,620.351 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, aligning director interests with shareholders.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

This filing is a routine disclosure of a director's compensation in the form of phantom stock units, which is a common practice in corporate governance to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include deferred equity-based awards like phantom stock units to incentivize long-term performance and retention.
• Companies such as Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize similar compensation structures for their directors.
• The specific amount and terms of the phantom stock units are typical for director compensation within the pharmaceutical industry.

Stakeholder Impact

• The acquisition of phantom stock units aligns the director's interests with those of the shareholders, incentivizing long-term value creation.

Key Dates